{"schema_version":"secwatch.filing_event.v1","accession":"0001937653-23-000026","form_type":"8-K","ticker":"ZYME","cik":"0001937653","company_name":"Zymeworks Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.095189+00:00","generated_at":"2026-06-11T19:37:11.562913+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Zymeworks Q2 2023 net loss narrows 45% to $75.5M; zanidatamab Phase 2b data show 41.3% ORR","bullets":["Revenue surged to $42.6M (from $7.4M) on Jazz collaboration; net loss improved 45% YoY to $75.5M.","Cash and marketable securities $431.4M; runway expected through at least end-2026.","Zanidatamab Phase 2b BTC results: cORR 41.3%, median DOR 12.9 months, median PFS 5.5 months.","Next IND candidate ZW220 (NaPi2b-TOPO1i ADC) targeting NSCLC/ovarian cancer; IND filing expected 1H 2025.","Appointed Carlos E. Campoy to board; reiterated 2023 non-GAAP cash burn guidance $110M-$130M."],"urls":{"canonical":"https://secwatch.observer/filing/0001937653-23-000026","json":"https://secwatch.observer/filing/0001937653-23-000026.json","markdown":"https://secwatch.observer/filing/0001937653-23-000026.md","text":"https://secwatch.observer/filing/0001937653-23-000026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937653/000193765323000026/0001937653-23-000026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937653/000193765323000026/zyme-20230810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T19:37:11.562913+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"915c9b8a942c34a3a728437bb6647bf4042b5c56","claim":"Zymeworks Inc. reported financial results for three and six months ended June 30, 2023.","evidence_excerpt":"On August 10, 2023 , Zymeworks Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1937653/000193765323000026/0001937653-23-000026-index.htm","confidence":0.5,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and six months ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}